SCYX: Pipeline Now Advancing on Multiple Fronts, With Focus on Newly Acquired SCY-770 for ADPKD; 1Q26 Earnings Recap

Research evidence excerpt

SCYX: Pipeline Now Advancing on Multiple Fronts, With Focus on Newly Acquired SCY-770 for ADPKD; 1Q26 Earnings Recap

May 12, 2026

Vamil Divan, M.D. vamil.divan@guggenheimpartners.com SCYX: Pipeline Now Advancing on Multiple Fronts,

212 823 6543 With Focus on Newly Acquired SCY-770 for ADPKD;

Daniel Krizay, Ph.D.

daniel.krizay@guggenheimpartners.com 1Q26 Earnings Recap

212 823 6561

Arseniy Shabashvili Key Message: SCYX released its 1Q 2026 results and provided a corporate update arseniy.shabashvili@guggenheimpartners.com yesterday after the close. A key focus of the business update was the company's 212 699 1971

recently acquired asset, SCY-770 (formerly PXL-770), and the completed $40M private

Edouard Mullarky, Ph.D. placement (discussed in our prior note HERE), which extends the company's cash

edouard.mullarky@guggenheimpartners.com runway to mid-2029. The company continues to expect to start a Phase 2 trial for

212 518 9579 SCY-770 in patients with autosomal dominant polycystic kidney disease (ADPKD) in

4Q 2026, with early efficacy data expected to be released in 2H 2027. On SCY-247, in

addition to their ongoing Phase 1 IV formulation study, the company is also now accepting

requests for access to oral SCY-247 via an expanded access program, from which

data will likely be presented at a later date. On Brexafemme, management informed usSCYX BUY that GSK-LON remains committed to the relaunch, but the exact timing and status of SCYNEXIS, Inc.

Sector: Global Biopharmaceuticals their communications with regulatory agencies is still unknown. For the quarter, financial

results came in below our expectations, primarily driven by the one-time ~$8.0M IPR&D

Company Update expense related to the SCY-770 acquisition and ~$0.8M in offering costs, both of which